Literature DB >> 21930965

Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans.

Tine Rugh Poulsen1, Allan Jensen, John S Haurum, Peter S Andersen.   

Abstract

The immune system is known to generate a diverse panel of high-affinity Abs by adaptively improving the recognition of pathogens during ongoing immune responses. In this study, we report the biological limits for Ag-driven affinity maturation and repertoire diversification by analyzing Ab repertoires in two adult volunteers after each of three consecutive booster vaccinations with tetanus toxoid. Maturation of on-rates and off-rates occurred independently, indicating a kinetically controlled affinity maturation process. The third vaccination induced no significant changes in the distribution of somatic mutations and binding rate constants implying that the limits for affinity maturation and repertoire diversification had been reached. These fully matured Ab repertoires remained similar in size, genetically diverse, and dynamic. Somatic mutations and kinetic rate constants showed normal and log-normal distribution profiles, respectively. Mean values can therefore be considered as biological constants defining the observed boundaries. At physiological temperature, affinity maturation peaked at k(on) = 1.6 × 10(4) M(-1) s(-1) and k(off) = 1.7 × 10(-4) s(-1) leading to a maximum mean affinity of K(D) = 1.0 × 10(-9) M. At ambient temperature, the average affinity increased to K(D) = 3.4 × 10(-10) M mainly due to slower off-rates. This experimentally determined set of constants can be used as a benchmark for analysis of the maturation level of human Abs and Ab responses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930965     DOI: 10.4049/jimmunol.1000928

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Combining different design strategies for rational affinity maturation of the MICA-NKG2D interface.

Authors:  Samuel H Henager; Melissa A Hale; Nicholas J Maurice; Erin C Dunnington; Carter J Swanson; Megan J Peterson; Joseph J Ban; David J Culpepper; Luke D Davies; Lisa K Sanders; Benjamin J McFarland
Journal:  Protein Sci       Date:  2012-08-10       Impact factor: 6.725

2.  "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.

Authors:  Chia Chi M Ho; Nan Guo; Jonathan T Sockolosky; Aaron M Ring; Kipp Weiskopf; Engin Özkan; Yasuo Mori; Irving L Weissman; K Christopher Garcia
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

3.  A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.

Authors:  Xiaoying Chen; Timothy Hickling; Eugenia Kraynov; Bing Kuang; Chuenlei Parng; Paolo Vicini
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

Review 4.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

5.  Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response.

Authors:  Yariv Wine; Daniel R Boutz; Jason J Lavinder; Aleksandr E Miklos; Randall A Hughes; Kam Hon Hoi; Sang Taek Jung; Andrew P Horton; Ellen M Murrin; Andrew D Ellington; Edward M Marcotte; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

6.  Identification and characterization of the constituent human serum antibodies elicited by vaccination.

Authors:  Jason J Lavinder; Yariv Wine; Claudia Giesecke; Gregory C Ippolito; Andrew P Horton; Oana I Lungu; Kam Hon Hoi; Brandon J DeKosky; Ellen M Murrin; Megan M Wirth; Andrew D Ellington; Thomas Dörner; Edward M Marcotte; Daniel R Boutz; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

7.  A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans.

Authors:  Kyle Saylor; Chenming Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2016-07-26       Impact factor: 4.219

Review 8.  Evolution of B cell analysis and Env trimer redesign.

Authors:  Gunilla B Karlsson Hedestam; Javier Guenaga; Martin Corcoran; Richard T Wyatt
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

9.  Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.

Authors:  Paola Martinez-Murillo; Karen Tran; Javier Guenaga; Gustaf Lindgren; Monika Àdori; Yu Feng; Ganesh E Phad; Néstor Vázquez Bernat; Shridhar Bale; Jidnyasa Ingale; Viktoriya Dubrovskaya; Sijy O'Dell; Lotta Pramanik; Mats Spångberg; Martin Corcoran; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

10.  Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.

Authors:  Alison M Betts; Nahor Haddish-Berhane; John Tolsma; Paul Jasper; Lindsay E King; Yongliang Sun; Subramanyam Chakrapani; Boris Shor; Joseph Boni; Theodore R Johnson
Journal:  AAPS J       Date:  2016-05-19       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.